203 related articles for article (PubMed ID: 37228028)
1. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
Gomez A; Jägerback S; Sjöwall C; Parodis I
Rheumatology (Oxford); 2024 Feb; 63(2):338-348. PubMed ID: 37228028
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
3. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.
Jägerback S; Gomez A; Parodis I
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38216728
[TBL] [Abstract][Full Text] [Related]
4. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
Lokhandwala T; Yue B; Coutinho AD; Bell CF
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
[TBL] [Abstract][Full Text] [Related]
5. Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Rheumatology (Oxford); 2024 Mar; 63(3):798-808. PubMed ID: 37228034
[TBL] [Abstract][Full Text] [Related]
6. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.
Parodis I; Gomez A; Lindblom J; Chow JW; Sjöwall C; Sciascia S; Gatto M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430417
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
[TBL] [Abstract][Full Text] [Related]
9. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
10. Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Front Immunol; 2022; 13():796508. PubMed ID: 35444642
[TBL] [Abstract][Full Text] [Related]
11. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
[TBL] [Abstract][Full Text] [Related]
12. Effect of Belimumab on Preventing
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau FA; Sjöwall C; Rovin BH
Kidney Int Rep; 2023 Sep; 8(9):1822-1830. PubMed ID: 37705915
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
[TBL] [Abstract][Full Text] [Related]
14. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
15. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
[TBL] [Abstract][Full Text] [Related]
17. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
Ramachandran S; Parks D; Kurtinecz M; Roth DA; Alfonso-Cristancho R
J Comp Eff Res; 2018 Jun; 7(6):581-593. PubMed ID: 29692179
[TBL] [Abstract][Full Text] [Related]
18. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
19. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]